

Rec'd PCT/PTO 21 OCT 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Mail Stop PCT/Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450 on the date shown below:

SEQUENCE LISTING  
SUBMISSION UNDER  
37 CFR §1.821  
Docket No. BB-137  
Serial No. 10/526,940

#6

October 17, 2005

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ulrich Deuschle, Stefanie Heck, Ingo Kober, Ulrike Bauer, and Imola Balogh  
Serial No. : 10/526,940  
Filed : March 8, 2005  
For : NR3B1 Nuclear Receptor Binding 3-Substituted Pyrazoles

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

STATEMENT UNDER 37 CFR §1.821

Sir:

In compliance with 37 CFR §§1.821 through 1.825, transmitted herewith is a substitute sequence listing in computer readable form and on paper. I hereby certify that the attached sequence listing in computer readable form is identical to the attached paper copy of the sequence listing and that no new material is introduced by this submission.

Respectfully submitted,

David Saliwanchik

David R. Saliwanchik  
Patent Attorney  
Registration No. 39,355  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: P.O. Box 142950  
Gainesville, FL 32614-2950

DRS/ehm

Attachments: Substitute Sequence Listing on Paper (12 pages) and in computer readable form (disk)